SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : PFE (Pfizer) How high will it go? -- Ignore unavailable to you. Want to Upgrade?

To: BigKNY3 who wrote (4635)7/28/1998 10:25:00 PM
From: puborectalis  Read Replies (1) | Respond to of 9523
 
Another way to play Big Pharma is with IMS Health(RX),a spin off of Dun and Bradstreet with a 20-25% growth rate and a big share buyback this fall.



To: BigKNY3 who wrote (4635)7/28/1998 11:18:00 PM
From: HiSpeed  Respond to of 9523
 
<" Drugs that do not have an economic potential of at least $250M are often not considered for advanced development and are increasingly considered non-strategic.">....

Who can blame them? If I've read correctly it costs about this much just to get a new drug through the FDA process so it makes sense the drug would need to generate over $250M.....

Can anyone else provide approximately what the cost is to develop a drug, get approval, and bring it to market?


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News